Recently Viewed
Clear AllToday’s Range
52 Week Range
Liquidity
Market cap
$604 Mln
Revenue (TTM)
$568 Mln
Net Profit (TTM)
$0 Mln
ROE
0.1 %
ROCE
-- %
P/E Ratio
27.2
P/B Ratio
3.2
Industry P/E
--
EV/EBITDA
8.3
Div. Yield
0 %
Debt to Equity
1.7
Book Value
$2.7
EPS
$0.3
Face value
--
Shares outstanding
67,368,052
CFO
$216.53 Mln
EBITDA
$400.75 Mln
Net Profit
$-395.99 Mln
|
Company
|
YTD
|
1 Month
|
3 Months
|
1 Year
|
3 Years
|
5 Years
|
10 Years
|
|---|---|---|---|---|---|---|---|
|
Bioventus Inc. Class A (BVS)
| 23.0 | 4.2 | 23.0 | 0.0 | 104.5 | -9.7 | -- |
|
BSE Sensex*
| -15.4 | -11.9 | -15.9 | -5.8 | 6.7 | 7.4 | 11.0 |
|
S&P Small-Cap 600#
| -5.8 | -5.3 | -13.7 | -6.3 | 5.3 | 3.0 | 5.5 |
|
Company
|
2025
|
2024
|
2023
|
2022
|
|---|---|---|---|---|
|
Bioventus Inc. Class A (BVS)
| -29.1 | 98.1 | 101.9 | -82.0 |
|
S&P Small-Cap 600
| 4.0 | 7.0 | 13.9 | -17.4 |
|
BSE Sensex
| 9.1 | 8.1 | 18.7 | 4.4 |
Is there a threat to the company's solvency?
Can creative accounting be detected through the financial numbers?
How did the company perform in the last one year?
5Y Avg -- 3Y Avg -- TTM --
P/E Ratio
--
--Min --Median --Max
P/B Ratio
--
--Min --Median --Max
Earnings Yield (%)
--
Earnings Yield (%) = EBIT / Enterprise value
PEG Ratio
--
Price = Price / Earnings to growth ratio
Company |
Price ($) | Market Cap ($ Mln) | Revenue (TTM) | Net Profit (TTM) | OPM (%) | ROE (%) | P/E | P/B |
|---|---|---|---|---|---|---|---|---|
|
Bioventus Inc. Class A (BVS)
|
9.2 | 603.6 | 568.1 | 22.7 | 10.3 | 13.7 | 27.2 | 3.2 |
| 7.8 | 5,176.8 | 6,552.2 | -530.2 | -4.1 | -9.2 | -- | 0.9 | |
| 36.1 | 5,222.6 | 3,436.5 | -8.6 | 2.2 | -0.4 | -- | 2.1 | |
| 25.9 | 3,989.0 | 2,719.5 | 47.0 | 8.4 | 1.6 | 86.6 | 1.3 | |
| 112.6 | 6,098.9 | 507.4 | -187.7 | -36.2 | -26.4 | -- | 8.9 | |
| 75.7 | 4,758.4 | 1,541.6 | 233.6 | 21.6 | 21.4 | 21.4 | 4.5 | |
| 178.0 | 9,411.8 | 1,526.9 | -151.5 | 20.0 | -17.1 | -- | 12.9 | |
| 329.0 | 12,879.6 | 1,403.7 | 177.7 | 14.7 | 13.8 | 72.5 | 9.2 | |
| 118.3 | 6,280.4 | 738.3 | 48.9 | 11.4 | 2.4 | 129.6 | 3.0 | |
| 32.1 | 13,409.8 | 6,178.4 | 626.5 | 13.0 | 11.9 | 22.1 | 2.6 |
Bioventus Inc., a medical device company, focuses on relieving pain and addressing musculoskeletal therapies in the United States and internationally. The company's product portfolio includes pain treatments, which comprise various intra-articular... and hyaluronic acid injections; peripheral nerve stimulation products, such as Durolane, GELSYN-3, and SUPARTZ for the treatment of knee osteoarthritis; and Stimrouter to treat chronic peripheral pain, and TalisMann provides stimulation to the targeted peripheral nerve, as well as XCELL PRP System, a benchtop device that processes whole blood to produce high-yield PRP with a 10-minute single-spin cycle. It also offers precision bone resection for patients with degenerative spine conditions and spinal deformities, as well as enables precision ultrasonic neuro and general surgery to address brain tumors and pathologies of the liver and other organs; and bone graft substitutes, including various products that facilitate optimal bone fusion. In addition, the company provides neXus, an ultrasonic surgical system; BoneScalpel, a surgical solution enabling precise cuts in hard tissue; BoneScalpel Access, for bone removal with visualization; SonaStar system, a precise ablation and removal of soft tissue; SonaStar Elite handpiece and accessories; SonicOne, an ultrasonic cleansing and debridement system; Osteoamp, an allograft-derived bone graft for orthopedic, neurosurgical, and reconstructive bone grafting procedures; Signafuse bone graft; Purebone, a natural osteoconductive scaffold; and Reficio demineralized bone matrix. The company's restorative therapies include minimally invasive fracture treatments and rehabilitation products. Its products also include Exogen, an ultrasound bone stimulation system. The company sells its products to healthcare institutions, physicians, patients, distributors and dealers. Bioventus Inc. was founded in 2011 and is headquartered in Durham, North Carolina. Address: 4721 Emperor Boulevard, Durham, NC, United States, 27703 Read more
Senior VP & CFO
Mr. Mark L. Singleton
Senior VP & CFO
Mr. Mark L. Singleton
Headquarters
Durham, NC
Website
Our rating system has guided millions of investors in the past 20 years.
The share price of Bioventus Inc Class A (BVS) is $9.15 (NASDAQ) as of 01-Apr-2026 16:00 EDT. Bioventus Inc Class A (BVS) has given a return of 104.49% in the last 3 years.
The P/E ratio of Bioventus Inc Class A (BVS) is 27.15 times as on 31-Mar-2026.
PE & PB ratio at the end of financial year.
| Year | P/E Ratio | P/B Ratio |
|---|---|---|
|
2025
|
22.58
|
2.79
|
|
2024
|
-20.35
|
4.61
|
|
2023
|
-2.13
|
1.91
|
|
2022
|
-1.00
|
0.49
|
|
2021
|
33.65
|
1.22
|
The 52-week high and low of Bioventus Inc Class A (BVS) are Rs 9.56 and Rs 5.81 as of 02-Apr-2026.
Bioventus Inc Class A (BVS) has a market capitalisation of $ 604 Mln as on 31-Mar-2026. As per SEBI classification, it is a Small Cap company.
Before investing in Bioventus Inc Class A (BVS), assess your goals, risk tolerance, and if the company aligns with your long-term plan. Carefully review its business model, financials, and valuation. Avoid making decisions based on tips or short-term trends.
$0.02
(
New Process Alert 
Seems like you've uploaded a wrong QR code. Please upload the QR code downloaded from MF Central platform.